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Neutralizing antibodies (NAbs) play a vital role in vaccine-induced protection against infection
with feline immunodeficiency virus (FIV). However, little is known about the appropriate
presentation of neutralization epitopes in order to induce NAbs effectively; the majority of the
antibodies that are induced are directed against non-neutralizing epitopes. Here, we demonstrate
that a subtype B strain of FIV, designated NG4, escapes autologous NAbs, but may be rendered
neutralization-sensitive following the insertion of two amino acids, KT, at positions 556–557 in the
fifth hypervariable (V5) loop of the envelope glycoprotein. Consistent with the contribution of this
motif to virus neutralization, an additional three subtype B strains retaining both residues at the
same position were also neutralized by the NG4 serum, and serum from an unrelated cat (TOT1)
targeted the same sequence in V5. Moreover, when the V5 loop of subtype B isolate KNG2, an
isolate that was moderately resistant to neutralization by NG4 serum, was mutated to incorporate
the KT motif, the virus was rendered sensitive to neutralization. These data suggest that, even in a
polyclonal serum derived from FIV-infected cats following natural infection, the primary
determinant of virus-neutralizing activity may be represented by a single, dominant epitope in V5.
INTRODUCTION
Feline immunodeficiency virus (FIV) was first isolated in
1986 in Petaluma, CA, USA, from a cat with an
immunodeficiency-like syndrome (Pedersen et al., 1987)
and is an important pathogen of domestic cats worldwide.
FIV is the feline homologue of human immunodeficiency
virus (HIV) and these viruses share many biological and
pathogenic features (Bendinelli et al., 1995; English et al.,
1993; Johnson et al., 1994), typified by a selective targeting
of CD4+ T lymphocytes and the induction of a progressive
immunosuppression (Ackley et al., 1990).
The induction of an effective humoral response against
lentivirus infection is a key element in the immunological
control of the disease, and the primary target for
neutralizing antibodies (NAbs) is the virus envelope
glycoprotein (Env) (Binley et al., 2004; Frost et al., 2005;
Wei et al., 2003). Env varies by up to 30% amongst FIV
subtypes (Hosie & Beatty, 2007) and, thus, the preparation
of an immunogen capable of inducing broadly neutralizing
antibody responses against such diverse isolates of FIV
would be of great value to the development of an FIV
vaccine. Further, the development of a vaccine against
FIV would have implications extending beyond veterinary
medicine; FIV is the only non-primate lentivirus that
induces AIDS-like symptoms in its natural host and, as
such, is a valuable animal model for both prophylactic and
therapeutic studies for HIV (Bendinelli et al., 1995; Elder
et al., 1998; Okada et al., 1994). Moreover, cats have the
advantage of being easier to breed and have shorter life
cycles than other animal models currently used for HIV
research (Miller et al., 2000).
Previous studies showed that vaccination with whole
inactivated vaccines or DNA vaccines can protect cats
against challenge with either low-virulence/homologous
strains of FIV, but not against virulent/heterologous
primary strains (reviewed by Hosie & Beatty, 2007). A
vaccine capable of protecting cats against infection with a
wide range of virulent primary isolates remains a challenge,
primarily because of the limited number of conserved
neutralization epitopes that have been identified and the
failure to present such epitopes appropriately in vaccines.
Steric factors may render neutralization epitopes inaccess-
ible to NAbs (Chiarantini et al., 1998; Labrijn et al., 2003),
whilst most of the antibodies generated by vaccination may
The GenBank/EMBL/DDBJ accession numbers for the novel FIV env
sequences generated in this study are GU066862–GU066866.
Supplementary tables showing oligonucleotides used for site-directed
mutagenesis of V5 and GenBank numbers for new and reference
sequences are available with the online version of this paper.
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be directed against non-neutralizing epitopes (Dhillon
et al., 2007; Richman et al., 2003). Accordingly, the
identification of conserved determinants for neutralization
will be an important advance in the design of the next
generation of FIV vaccines.
Understanding the biological basis for the induction of
antibodies with broad neutralizing activity is pivotal to the
development of efficacious lentivirus vaccines and to the
generation of vaccines that will protect against a broad
range of primary isolates. Encouraging results have
indicated that it is possible to protect cats against challenge
with primary FIV isolates, depending on their regional
distribution. By vaccinating cats with a whole inactivated
vaccine based on the subtype B Pisa M2 strain, cats were
protected from natural challenge with subtype B isolates of
FIV (Pistello et al., 1997). It has been suggested that
subtype B isolates may be more ancient and, accordingly,
more host-adapted (Bachmann et al., 1997), hence they
may be more readily neutralizable by the host humoral
response. In contrast, whilst subtype A viruses display
similar levels of non-synonymous mutations, such viruses
display half as many synonymous mutations, suggesting a
more recent spread and a lower level of host–virus
adaptation (Bachmann et al., 1997). As the major FIV
subtypes are restricted in their global distribution, it has
been proposed that it may be necessary to design several
regional vaccines rather than a single, worldwide-protective
vaccine (Steinrigl & Klein, 2003).
In this study, we investigate the initial observation that a
subtype B strain resisted neutralization by its homologous
serum. By applying targeted mutagenesis across the env
gene, we identified the V5 loop as the primary determinant
of escape from neutralization and localized the primary
determinant to a lysine–threonine (KT) motif. Additional
subtype B strains bearing the same motif were also sensitive
to neutralization. Furthermore, incorporation of these
residues into a neutralization-resistant subtype B strain
rendered the virus more sensitive to neutralization,
confirming the monospecificity of the neutralizing serum.
These data indicate that the functional neutralizing
response in natural infection with FIV may be highly
specific and that immune evasion in vivo may stem from
the mutation of as few as two amino acids in the V5 loop.
RESULTS
Phylogenetic analysis
An unrooted neighbour-joining phylogenetic tree was
generated based on 651 nt spanning the env V3–V5
sequence from the five isolates included in the study, as
well as reference sequences from subtypes A, B, C, D and E.
The phylogenetic tree (Fig. 1) demonstrates that the five
Japanese isolates were genetically related and clustered
within subtype B with bootstrapping support of 100%.
KNG1 and TOT1 were highly similar at the nucleotide level
and indeed had identical V3–V5 amino acid sequences and
clustered together on a single tree branch (Fig. 1).
Cats show different NAb responses to
homologous and heterologous strains
Sera from cats KNG1 and TOI1 showed no evidence of
neutralizing activity against any of the pseudotypes tested,
including those bearing their homologous Env proteins,
and serum from cat KNG2 showed no neutralizing activity
against the KNG1, NG4 or TOT1 pseudotypes, moderate
neutralizing activity against the KNG2 pseudotype and
weak neutralizing activity against the TOI1 pseudotype
(Table 1). In contrast, sera from cats NG4 and TOT1
showed strong neutralizing activity against pseudotypes
expressing Env proteins of the heterologous KNG1, TOT1
and TOI1 strains, and moderate responses against
pseudotypes expressing the Env of strain KNG2. The
pseudotype expressing the NG4 Env resisted neutralization
by four heterologous sera and showed only weak
neutralizing activity against its homologous serum
(Table 1). Although KNG1 and TOT1 shared similar env
Fig. 1. Midpoint-rooted neighbour-joining tree of the FIV V3–V5
env gene sequence. The tree shows the five Japanese sequences
included in the study (in bold type), as well as reference
sequences from subtypes A, B, C, D and E.
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sequences (97% similarity), they did not induce similar
humoral immune responses in their respective hosts.
Escape from homologous neutralization by NG4
NG4 was neutralized only weakly or resisted neutralization
by the two cross-neutralizing sera NG4 and TOT1,
respectively. The finding that NG4 was neutralized only
weakly by its homologous serum, a serum that cross-
neutralized the other four viruses, may indicate the
evolution in vivo of a neutralization-escape mutant that,
at the time of sampling, was the dominant species in the
periphery, as five independent Env clones for each virus
were sequenced, all of which gave rise to identical V5
amino acid sequences (data not shown). However, as blood
samples from cat NG4 at earlier time points in infection
were not available, it was not possible to identify earlier
strains that were most likely to have contributed to the
generation of the NAbs. However, given the similarity
between the five subtype B isolates, sites of amino acid
divergence from the consensus sequence that were
identified in NG4 would be likely to contribute to the
relative resistance of this strain to neutralization by its
homologous serum. Accordingly, these non-synonymous
residues were targeted by site-directed mutagenesis in an
attempt to render NG4 more sensitive to neutralization by
its homologous serum. Initially, Env was mutated at the V3
loop, a known target for NAbs (Lombardi et al., 1993;
Osborne et al., 1994). A glutamine residue (377) was
substituted with a histidine (Q377H), resulting in a net
increase in the charge of the V3 loop. However, the Q377H
mutation did not render NG4 more sensitive to neutral-
ization (Fig. 2). Next, the NG4 Env was mutated at the
crown of the predicted V5 loop (Fig. 3), targeting serine
residue 550 (S550N), creating a potential site for N-linked
glycosylation. When tested against its homologous serum,
the S550N mutant did not show enhanced sensitivity to
neutralization (Fig. 2; wild type, 46% neutralization at a
1 : 10 dilution; S550N, 38% at a 1 : 10 dilution), indicating
that the absence of asparagine 550 alone and ablation of the
predicted site for N-linked glycosylation did not contribute
to the escape from neutralization by homologous serum.
The NG4 Env was then mutated within the V5 loop by the
insertion of two amino acids, lysine and threonine, at
positions 556 and 557 [S556(KT)557K]. Interestingly, this
mutation rendered NG4 sensitive to neutralization, with
strong neutralizing activity (98%) observed at a 1 : 10
dilution (Fig. 2a, b). Moreover, the S556(KT)557K
insertion also rendered NG4 sensitive to the broadly
neutralizing TOT1 serum (Fig. 2c, d), indicating that,
despite the independent origins of the two viruses, both
cats responded to infection by targeting V5. Next, we asked
whether the increase in polarity afforded by the inserted
lysine residue contributed to the formation of the
neutralizing determinant. An S556(K)557K mutant was
prepared in which only a lysine residue was inserted. The
NG4 S556(K)557K mutant was tested against NG4 serum
and showed an intermediate pattern of neutralization
(Fig. 2), indicating that, whilst the lysine residue was clearly
important, the additional threonine residue enhanced the
formation of the neutralizing determinant. These data
emphasize the dominance of V5 in the neutralization of
FIV and are consistent with a hypothesis whereby the
broadly neutralizing NG4 serum selected for mutant
viruses bearing a deletion in V5 in the host animal.
Neutralization sensitivity of KNG2
Of the five isolates studied, KNG2 was the most divergent
at V5. In comparison with the other strains, KNG2 was
moderately sensitive to neutralization by all sera tested,
including the NG4 and TOT1 sera that showed strong
neutralizing activity against KNG1, TOT1 and TOI1. Based
on our finding that NG4 could be rendered sensitive to
neutralization by a single change in the amino acid
sequence of the V5 loop, we asked whether the partial
resistance of KNG2 was conferred by its divergent V5 loop.
Firstly, a KNG2 mutant was prepared bearing a DN556KT
mutation, targeting the same residues shown earlier to
confer neutralization sensitivity upon NG4. The DN556KT
mutation did not display improved sensitivity to neutral-
ization relative to the wild type. As the sequence of KNG2
diverged from the consensus at 7 aa, we considered that the
context of the mutation may have been important for
formation of the epitope. Accordingly, the V5 loop was
mutated in stages towards identity with the (highly
sensitive) KNG1 and TOT1 sequences; initially a 5 aa
change was created (553NGNDN558A553DNSDT558),
followed by the full mutation (551STNGNDNKMT558A
551GTDNSKTKMA558). Both KNG2 mutants were then
tested for sensitivity to neutralization by the TOT1 serum.
The 551STNGNDNKMT558A551GTDNSKTKMA558 va-
riant was neutralized efficiently by the TOT1 serum, whilst
the 553NGNDN558A553DNSDT558 mutant showed an
intermediate sensitivity (Fig. 4). The conversion of KNG2
from neutralization-resistant to neutralization-sensitive by
changing the sequence of V5 to a sequence similar to those
of the neutralization-sensitive KNG1 and TOT1 strains is
Table 1. Percentage neutralization values (at a 1 : 10 serum
dilution) for five HIV(FIV) pseudotyped viruses tested against
homologous and heterologous sera for neutralization
Neutralizing activity is categorized as weak (40–59%), moderate
(60–79%) or strong (80–100%). Negative values indicate in vitro
enhancement of infection and are not significant.
Env Serum
KNG1 KNG2 NG4 TOT1 TOI1
KNG1 27 212 86 99 278
KNG2 67 71 73 64 61
NG4 4 25 46 231 215
TOT1 231 248 80 99 257
TOI1 15 41 98 96 28
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consistent with V5 being a primary determinant of
neutralization sensitivity and the specificity of the neutral-
izing sera.
The results of this study indicate the importance of V5 to
antibody-mediated neutralization of FIV. Whilst anti-V5
antibodies can neutralize primary isolates of FIV very
efficiently, the virus appears able to escape neutralization
readily by mutating V5. What, then, are the prospects for
designing an FIV vaccine that induces broadly neutralizing
antibodies targeting V5? A comparison of published V5
sequences (Fig. 5) would suggest that the V5 region has
highly conserved structural features, such as the cysteines at
positions 533, 546, 548 and 561 (numbering as in KNG1
and 2, TOI1 and TOT1; Fig. 5). However, the region
between cysteine residues 548 and 561 appears to be
remarkably flexible in its ability to tolerate amino acid
substitutions, glycosylation (potentially O- and N-linked)
and length polymorphisms, suggesting that it is under
pressure to vary from the host immune response. The
relative conservation of the region between cysteines 533
and 548 may indicate that this region is either inaccessible
or structurally constrained, perhaps through interactions
with adjacent regions of Env. If possible, targeting the
humoral response to this region may induce more broadly
neutralizing antibodies.
DISCUSSION
In this study, we demonstrate that the V5 loop of FIV Env
is a primary target for virus-neutralizing antibodies.
Although previous studies in vitro indicated that the V3
loop was a major determinant for virus neutralization,
subsequent studies revealed that the significance of
antibodies targeting this region to the neutralizing response
had been overemphasized by the cellular substrate used to
quantify neutralization. Formerly, assays were based on
inhibiting infection of Crandell feline kidney (CrFK) cells
with ‘CrFK-adapted’ strains of virus. Prior to measuring
neutralization in this system, the challenge virus had to be
selected for growth in CrFK cells, thereby selecting for
viruses that were capable of CD134-independent infection
through a direct interaction with CXCR4 (analogous to
CD4-independent infection with HIV). The V3 loop plays
a critical role in the FIV Env–CXCR4 interaction;
accordingly, CrFK-based assays exaggerated the import-
ance of NAbs binding this region. Subsequent studies
Fig. 2. Neutralization of wild-type NG4 (#) and NG4 mutants [h, NG4 S550N; h, NG4 Q377H; e, NG4 S556(K)557K;
g, NG4 S556(KT)557K] by homologous serum (a, b) and by TOT1 serum (c, d). (a, c) Luciferase activity (c.p.m.) with
successive dilutions of NG4 serum (dilution factors 1 : 10, 1 : 100, 1 : 1000 and 1 : 10 000; no serum, ‘). (b, d) Fold
neutralization relative to no-serum control. Each point represents the mean±SEM (n53).
FIV Env V5
http://vir.sgmjournals.org 245
revealed that, when primary (non-CrFK-adapted) isolates
were assayed on interleukin-2-dependent T cells, the
correlation between the efficiency of virus neutralization
and the response to V3 was diminished. Here, we extend
previous studies that indicated that, in biologically relevant
in vitro systems, the variable loops V4 and V5 appear to be
the major targets for effective NAbs. Moreover, we found
that, in polyclonal sera from infected cats, deletion of as
few as two amino acids from V5 converts a virus from a
strongly neutralized to a weakly neutralized or neutraliza-
tion-resistant phenotype. Each of the isolates described in
the current study was confirmed as being CD134-
dependent by plating the virus pseudotypes on target cells
expressing CD134. No evidence of CD134-independent
infection via CXCR4 alone was detected (data not shown),
confirming that the isolates were primary and not cell-
culture-adapted.
Amongst the variable regions in FIV Env, V5 appears to be
highly polymorphic between strains, with variations in
amino acid sequence, glycosylation and extended stretches
of serine and threonine residues being common. These data
suggest that there is a selective pressure within the host for
variation in V5, consistent with escape from an effective
immune response. The fact that minimal variation in V5 is
sufficient to either reduce substantially or ablate completely
the neutralizing capacity of the host humoral response is of
concern for the design of effective FIV vaccines. How, then,
are we to elicit broadly neutralizing antibodies in vivo?
Clearly, the V4 and V5 loops are exposed and immuno-
genic, and antibodies targeting these regions neutralize
virus. However, it would appear that these regions may
represent little more than a decoy for the virus, presenting
the immune system with an easy target for NAbs. By the
time functional NAbs develop, virus variants that can
escape the monospecific serum may have already evolved in
vivo. The solution to this dilemma would appear to lie in
the identification of framework determinants in Env that
induce antibodies that are broadly active, refocusing the
immune response either by silencing the immunodomi-
nant (but ultimately ineffectual) determinants in V4 and
V5, or by presenting them in a such a way as to induce
antibodies that recognize structures or motifs that are
difficult or impossible for the virus to vary.
Previous studies have demonstrated the importance of V5
in virus neutralization (Giannecchini et al., 2001; Pistello
et al., 2003; Siebelink et al., 1995). V5 was mapped by using
synthetic peptides for a possible linear epitope based on the
sequence of the 19k1-560 strain (Siebelink et al., 1995), and
it was demonstrated that a single mutation at position 560
may be involved concurrently with another mutation at
483 (V4 loop) in one or more conformational epitopes,
but no linear epitope was mapped in V5. Further, two
independent mutations have been reported that resulted in
the creation of potential N-linked glycosylation sites in V4
(K481N) and V5 (S557N) and which contributed to the
conversion from a neutralization-sensitive to a neutraliza-
tion-resistant phenotype (Giannecchini et al., 2001; Pistello
et al., 2003). In comparison, the conversion from a weakly
neutralized or neutralization-resistant to a strongly neu-
tralized phenotype described herein was mediated by
Fig. 3. Schematic structural model of the FIV SU protein, illustrating the locations of the Q377H mutation in V3 and of the V5
loop. The inset displays a comparison of the sequences from the five study strains, KNG1, KNG2, TOI1, TOT1 and NG4, and
the reference strain TM2 (GenBank accession no. M59418).
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mutation of V5 alone. The V5 loop of FIV Env is highly
variable among isolates. Variation occurs not only within
the amino acid sequence, but also in the length of the
central region (up to 14 residues) towards the end of the
loop formed by disulfide-bond linkage, indicating that this
particular region may play a significant role in virus
evolution and escape from neutralization. It is notable that
the length polymorphisms in this region are attributable to
a reiteration of codons encoding serine and threonine
residues. Threonine and serine have hydroxyl side chains
and may, potentially, undergo O-linked glycosylation. It is
generally believed that, due to their small molecular size,
O-linked oligosaccharides have only minor effects on the
formation of the glycan shield on HIV Env compared with
N-linked oligosaccharides. However, these oligosaccharides
usually have diverse structures with no common carbohyd-
rate core and it is difficult to predict how efficient they may
be in shielding neutralization epitopes, especially when
there are several adjacent molecules (Bernstein et al., 1994).
Moreover, X-ray crystallography studies on HIV-1 gp120
showed that glycosylation may have significant effects on
the conformational stability of Env, as well as an indirect
effect on more distant sequences along the secondary
structure. This, in turn, would affect the interaction
between the epitope and NAbs, rendering epitopes less
accessible for antibody binding (Huang et al., 1997).
In conclusion, we identified a neutralization determinant
in the FIV V5 loop that is associated with the conversion of
strongly neutralized to weakly neutralized or neutraliza-
tion-resistant strains. The determinant is apparently linear
and involves at least 10 aa (GTDNSKTKMA) within the V5
region, a highly variable region amongst FIV strains. The
identification of this neutralization determinant will
inform vaccine design in the future in order to induce
more potent NAb responses.
METHODS
Blood samples and collection of peripheral blood mono-
nuclear cells (PBMCs) and sera. All blood samples were collected
from five naturally infected cats from three different regions of
Japan (isolate NG4 originated in Isikawa, KNG1 and KNG2 from
Kanagawa and TOI1 and TOT1 from Tokyo). Four cats (KNG1, NG4,
TOT1 and TOI1) were apparently healthy and displayed no clinical
signs (analogous to the asymptomatic stage of HIV infection), whereas
one cat, KNG2, presented with severe gingivostomatitis (analogous to
the symptomatic stage of HIV infection). PBMCs were fractionated
from 5 ml heparinized whole blood by centrifugation over Ficoll-Paque
density separation medium (GE Healthcare). Aliquots of sera were
stored at 280 uC prior to use in neutralization assays.
Cloning and pseudotype virus production. DNA was extracted
from PBMCs by using a DNA Whole Blood extraction kit (Qiagen).
The FIV env gene was amplified by PCR, using forward and reverse
primers containing recognition sites for the restriction enzymes SalI
and NotI, and then cloned into a low-copy-number eukaryotic
expression vector, VR1012 (VICAL Inc.). To prepare HIV(FIV)
pseudotypes, 3.36105 HEK-293T cells were transfected with 5 mg
VR1012 expressing the FIV env clone and 5 mg pNL-Luc-E-R+
(Connor et al., 1995) (an Env-deleted HIV provirus that incorporates
a luciferase reporter gene) by using SuperFect reagent (Qiagen),
following the manufacturer’s instructions. Culture supernatants were
harvested at 48–72 h post-transfection, filtered at 0.45 mm and frozen
at 280 uC until required.
DNA sequencing. The FIV env genes were sequenced by using a
BigDye Terminator v1.1 kit (Applied Biosystems). The reaction
mixture consisted of 100 ng purified DNA ml21, 3.2 pmol each
primer, 4 ml sequencing buffer and 2 ml sequencing enzyme in 20 ml
reactions. Cycling conditions were one cycle at 96 uC for 1 min,
followed by 25 cycles at 96 uC for 10 s, 50 uC for 5 s and 60 uC for
4 min. Sequencing was performed by using an ABI3700 automated
capillary array sequencer (Applied Biosystems). Raw chromato-
graphic data were analysed by using ‘Contig Express’ sequence-
analysis software within the Vector NTI suite of programs
(Invitrogen).
Fig. 4. Conferral of neutralization sensitivity to KNG2 by V5-loop
transfer. (a) Luciferase activity (c.p.m.) with successive dilutions of
TOT1 serum (dilution factors 1 : 10, 1 : 100, 1 : 1000 and
1 : 10000; no serum, ‘). (b) Fold neutralization relative to no-
serum control. Each point represents the mean±SEM (n53).
#, KNG2 WT; h, KNG2 556KT557; h, KNG2 553DNSDT558;
e, KNG2 551GTDNSKTKMA558.
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Multiple alignments and phylogenetic analysis. Nucleotide
sequence analysis was performed on a 651 nt fragment spanning
the V3–V5 region of the FIV env gene. The generated consensus
sequence comprised sequences of the five isolates included in the
study, as well as reference sequences. Multiple alignments were
performed by using the CLUSTAL_X (version 2.0.1) (Larkin et al., 2007)
and BioEdit (version 7.0.9.0) (Hall, 1999) applications, followed by
manual adjustment to maximize similarities. Alignments were
translated and the resulting amino acid-based alignments were used
as an exact guide for repositioning of improper gapping, particularly
where sequences differed in length. DNA distance matrices were
calculated with DNADIST from the PHYLIP software package (version
3.68, 2008) (Felsenstein, 1989) using the F84 model and an empirical
transition/transversion ratio of 2. Phylogenetic trees were constructed
by the neighbour-joining method. Robustness of the tree was
evaluated by bootstrap analysis on 1000 replicates to assess the
support at each of the internal nodes of the neighbour-joining tree.
The phylogenetic tree was committed for final editing and graphical
representation using MEGA4 (Tamura et al., 2007).
Virus-neutralization assay. Twenty-five microlitres of heat-inacti-
vated serum (four tenfold serial dilutions starting at a 1 : 10 dilution) and
25 ml luciferase HIV(FIV) pseudotypes were co-incubated in triplicate
wells of 96-well flat-bottom CulturPlate-96 assay plates (Perkin Elmer) for
1 h at 37 uC before 50 ml CLL-CD134 cells (56105 cells ml21) (Willett et
al., 2006) were added. At 72 h post-infection, 100 ml Steadylite HTS
(Perkin Elmer) luciferase substrate was added to each well and luciferase
activity was quantified by single photon counting on a MicroBeta
luminometer (Perkin Elmer). The percentage neutralization was calculated
as follows: [(no-serum luciferase activity2serum luciferase activity)/no-
serum luciferase activity]6100. Empirical values of ¢80 and 60–79%
were considered as strong and moderate neutralization, respectively.
Site-directed mutagenesis. Mutations were introduced into the
FIV env gene by using a QuikChange II Site-Directed Mutagenesis kit
(Stratagene) according to the manufacturer’s protocol. Briefly, each
50 ml reaction contained 50 ng DNA (VR1012 plasmid carrying the
FIV env gene), 125 ng each primer, 16 Pfu reaction buffer, 1 ml
dNTP mix and 2.5 U PfuUltra high-fidelity DNA polymerase
(included in the QuikChange kit). Cycling temperatures were as
follows: initial denaturation at 95 uC for 30 s, followed by 12–18
cycles of denaturation at 95 uC for 30 s, annealing at 50 uC for 1 min
and extension at 68 uC for 7 min with no final extension hold. The
product was then treated with DpnI endonuclease in order to digest
the methylated parental DNA template. DpnI-treated DNA was then
transformed into XL1-Blue Supercompetent cells (included in the
QuikChange kit) and the env gene was sequenced to confirm the
presence of the desired mutation. Oligonucleotide primers for
mutagenesis are detailed in Supplementary Table S1, available in
JGV Online.
Nucleotide sequence accession numbers. GenBank accession
numbers for control reference sequences used in the phylogenetic
analysis and new sequences reported in this study are listed in
Supplementary Table S2 (available in JGV Online).
ACKNOWLEDGEMENTS
We would like to thank the Kyoritsu–Seiyaku Corporation for
financial support, the Faculty of Veterinary Medicine and Pfizer
Corporation for scholarship funding for A. S. and the veterinary
practitioners who collected samples from naturally infected cats for
this study. N. L. and E. L.M. are funded by a grant awarded to B. J.W.
and M. J. H. from the Wellcome Trust.
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